The Food and Drug Administration has approved the 2025-2026 formulation of Nuvaxovid (COVID-19 Vaccine, Adjuvanted).

Comirnaty (LP.8.1-adapted monovalent COVID-19 vaccine, mRNA) has been approved for active immunization to prevent COVID-19 in older individuals and patients at increased risk for severe disease.

The U.S. Food and Drug Administration will now require COVID-19 vaccines from Pfizer/BioNTech and Moderna to use expanded warning labels with more information about the risk of a rare heart condition ...

The Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax ® and mNexspike ®. The updated mRNA vaccines target the LP.8.1 variant of ...